Arotide(25 mcg+125 mcg)/puff

Arotide (25 mcg+125 mcg)/puff is a combination inhaled medicine containing a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate). It is indicated for the following:

Established / FDA-approved uses

• Asthma (long-term maintenance): Regular twice-daily maintenance treatment of asthma in patients aged 4 years and older who are not adequately controlled on a long-term asthma-control medication (such as an inhaled corticosteroid alone), or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a long-acting beta-2 agonist (LABA).
• Chronic obstructive pulmonary disease (COPD): Long-term, twice-daily maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD, including chronic bronchitis and/or emphysema.

Important limitations

• Arotide (25 mcg+125 mcg)/puff is not a rescue inhaler and must not be used to relieve acute bronchospasm or an acute asthma/COPD exacerbation; a short-acting bronchodilator should be used for acute symptoms.
• It is not indicated as the first medicine for treating asthma; it is used as combination maintenance therapy once an inhaled corticosteroid alone is judged insufficient, or when combination therapy is otherwise appropriate.

Each dose of Arotide (25 mcg+125 mcg)/puff combines two active ingredients delivered together by a metered-dose inhaler (MDI) or dry powder inhaler (DPI):

• Salmeterol (as salmeterol xinafoate) — a long-acting beta-2 adrenergic agonist (LABA).
• Fluticasone propionate — an inhaled corticosteroid (ICS).

It is available in several fixed-dose strength combinations, commonly expressed as salmeterol/fluticasone propionate micrograms (mcg) per actuation, such as 25/50, 25/125, 25/250 (MDI) and 50/100, 50/250, 50/500 (DPI). The exact strength and inhaler device should be selected by the prescribing physician based on disease severity.

Arotide (25 mcg+125 mcg)/puff is a fixed-dose combination inhaler that brings together two complementary mechanisms for chronic airway disease: a long-acting bronchodilator and an anti-inflammatory corticosteroid, delivered directly to the lungs.

Salmeterol relaxes airway smooth muscle by stimulating beta-2 adrenergic receptors, producing bronchodilation that lasts approximately 12 hours per dose. Fluticasone propionate is a potent, locally-acting corticosteroid that reduces airway inflammation, mucus production, and bronchial hyperresponsiveness that underlie asthma and COPD. Used together twice daily, they provide more comprehensive control of chronic airway obstruction than either agent alone.

Arotide (25 mcg+125 mcg)/puff is available as a metered-dose inhaler (MDI, using a propellant) and as a dry powder inhaler (DPI, breath-activated, propellant-free), in several strengths to allow dose individualization by a physician.

Arotide (25 mcg+125 mcg)/puff belongs to the therapeutic class of combination inhaled bronchodilator and corticosteroid preparations, used in the long-term management of obstructive airway diseases. It combines:

• A long-acting beta-2 agonist (LABA) bronchodilator, and
• An inhaled corticosteroid (ICS) anti-inflammatory agent.

Arotide (25 mcg+125 mcg)/puff works through the combined, complementary actions of its two components:

Salmeterol (long-acting beta-2 agonist)

Salmeterol selectively stimulates beta-2 adrenergic receptors on airway smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP. This relaxes bronchial smooth muscle and produces bronchodilation that begins within 10-20 minutes and lasts for approximately 12 hours, allowing twice-daily dosing.

Fluticasone propionate (inhaled corticosteroid)

Fluticasone propionate has potent local anti-inflammatory activity within the airway. It reduces the number and activity of inflammatory cells (eosinophils, mast cells, lymphocytes, macrophages), decreases production of inflammatory mediators, and reduces airway mucosal edema and mucus secretion, thereby reducing bronchial hyperresponsiveness and the frequency of exacerbations. Systemic absorption is low with correct inhaler technique, though some systemic corticosteroid effect can occur, particularly with higher doses or prolonged use.

Used together, the LABA component provides sustained symptom control and bronchodilation while the ICS component addresses the underlying airway inflammation, and evidence indicates the ICS component also reduces the LABA-associated safety signal seen with LABA monotherapy in asthma.

Arotide (25 mcg+125 mcg)/puff is for oral inhalation only and must not be swallowed or used with a nebulizer/spacer device not designed for it.

• Use at the same times each day, approximately 12 hours apart (e.g., morning and evening), with or without food.
• For the dry powder inhaler (DPI): breathe in quickly and deeply through the device; do not exhale into the device.
• For the metered-dose inhaler (MDI): shake if required by the specific device, exhale fully away from the inhaler, then inhale slowly and deeply while actuating the device, and hold the breath for about 10 seconds.
• Rinse the mouth with water and spit it out after every dose, without swallowing, to reduce the risk of oral thrush (candidiasis) and hoarseness.
• Do not use a second, separate long-acting beta-2 agonist (LABA) inhaler while using this medicine.
• Do not stop or change the dose without consulting the physician, even if breathing feels better.

Arotide (25 mcg+125 mcg)/puff has the following well-established, clinically significant interactions:

• Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, clarithromycin): can markedly increase systemic exposure to the fluticasone component, increasing the risk of systemic corticosteroid effects, including adrenal suppression and Cushingoid features; co-administration should generally be avoided, and if unavoidable, the patient should be monitored closely.
• Other LABAs or sympathomimetic agents: concurrent use of another LABA or additional sympathomimetic bronchodilator can potentiate cardiovascular effects (tachycardia, arrhythmia) and is not recommended.
• Beta-blockers (including cardioselective agents and eye drops): may reduce the effect of the salmeterol component and can, in susceptible individuals, provoke bronchospasm; use with caution and only if necessary, under medical supervision.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: may potentiate the cardiovascular effects of salmeterol (e.g., prolonged QT interval, tachyarrhythmia); use with caution.
• Non-potassium-sparing diuretics (e.g., loop or thiazide diuretics): ECG changes and/or hypokalemia associated with beta-agonists may worsen with concomitant diuretic use; monitor potassium and ECG where clinically indicated.

Side effects of Arotide (25 mcg+125 mcg)/puff vary by indication and may include:

Common side effects

• Upper respiratory tract infection, throat irritation/pharyngitis
• Oral thrush (candidiasis) and hoarseness/dysphonia — reduced by rinsing the mouth after use
• Headache
• Nausea, vomiting
• Musculoskeletal pain, muscle cramps
• Increased incidence of pneumonia has been observed in COPD patients using inhaled corticosteroid-containing products

Less common but important effects

• Paradoxical bronchospasm (immediate worsening of wheezing after a dose) — discontinue and seek urgent medical review if this occurs.
• Tremor, palpitations, tachycardia (from the LABA component)
• Signs of systemic corticosteroid effect with prolonged/high-dose use (see Precautions and Warnings).
• Hypersensitivity reactions, including rash, urticaria, and rarely angioedema or anaphylaxis.

Arotide (25 mcg+125 mcg)/puff should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. There is limited controlled data on its use in pregnant women; however, poorly controlled asthma or COPD itself carries risks to both mother and fetus (including preeclampsia, prematurity, and low birth weight), so treatment is generally continued under close physician supervision when clinically necessary rather than stopped abruptly.

It is not known whether salmeterol or fluticasone propionate passes into breast milk in clinically significant amounts. A physician should be consulted to weigh the benefits of treatment for the mother against any potential risk to the breastfeeding infant before use during lactation.

Pregnant or breastfeeding women should not start or stop Arotide (25 mcg+125 mcg)/puff without first consulting their physician.

Boxed warning: LABA and asthma-related death

Medicines in the long-acting beta-2 agonist (LABA) class, when used as monotherapy for asthma (without an inhaled corticosteroid), are associated with an increased risk of asthma-related death. Arotide (25 mcg+125 mcg)/puff combines a LABA with an inhaled corticosteroid in a single inhaler, which mitigates but does not eliminate this class-wide concern. Patients must use it exactly as prescribed and must not add a separate LABA-containing inhaler.

Not for acute symptoms

Arotide (25 mcg+125 mcg)/puff is not a rescue inhaler and does not relieve acute bronchospasm; a short-acting bronchodilator must be available for acute symptoms.

Paradoxical bronchospasm

As with other inhaled medicines, paradoxical bronchospasm can occur, with an immediate increase in wheezing after dosing. If this occurs, discontinue Arotide (25 mcg+125 mcg)/puff immediately and seek alternative therapy.

Local and systemic corticosteroid effects

Oral candidiasis and hoarseness may occur; rinsing the mouth after each dose reduces this risk (see Administration). With long-term use, particularly at higher doses, inhaled corticosteroids can cause systemic effects such as adrenal suppression, reduced growth velocity in children, and decreased bone mineral density; the lowest effective dose should be used and growth should be monitored periodically in children.

Increased pneumonia risk in COPD

An increased incidence of pneumonia has been observed in patients with COPD using inhaled corticosteroid-containing products; patients should be monitored for signs of pneumonia, which can overlap with COPD exacerbation symptoms.

Cardiovascular and other precautions

Use with caution in patients with cardiovascular disease (including arrhythmia, coronary artery disease), convulsive disorders, thyrotoxicosis, or diabetes mellitus, as beta-agonists can cause tachycardia, palpitations, and transient elevations in blood glucose. Do not exceed the prescribed dose or frequency.

Overdose of Arotide (25 mcg+125 mcg)/puff can result in exaggerated effects of both components: from the salmeterol component, effects such as tachycardia, palpitations, tremor, headache, muscle cramps, high blood pressure or low blood pressure, and prolonged QT interval with arrhythmias can occur; from the fluticasone component, excessive or prolonged overdose may suppress the body's own cortisol (adrenal) function.

If an overdose is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt to manage a suspected overdose at home; cardiac monitoring and supportive care may be required in a medical facility.

Store at room temperature (below 30°C), away from direct light, heat, and moisture. Do not puncture, break, or expose the canister/device to fire or high heat, even when apparently empty. Keep the inhaler dry and keep out of reach of children.

Renal impairment

No dose adjustment of Arotide (25 mcg+125 mcg)/puff is specifically established for renal impairment; use with routine clinical monitoring.

Hepatic impairment

Fluticasone propionate is metabolized in the liver; patients with hepatic impairment may have increased systemic exposure to the corticosteroid component and should be monitored closely for systemic corticosteroid effects. No formal dose adjustment has been established; use the lowest effective dose.

Elderly

No specific dose adjustment is required based on age alone, but elderly patients, particularly those with cardiovascular disease, osteoporosis risk, or diabetes, should be monitored appropriately during treatment.

Pediatric use

See Pediatric Uses section.

Arotide (25 mcg+125 mcg)/puff is intended for long-term, regular maintenance treatment rather than short courses. It should be used continuously as prescribed, even during symptom-free periods, since stopping treatment can lead to worsening of underlying airway inflammation. The physician will periodically reassess control and may adjust the dose (including stepping down to the lowest effective corticosteroid dose) or duration based on the patient's response; it should not be stopped or changed by the patient without medical advice.

Combination long-acting beta-2 agonist (LABA) and inhaled corticosteroid (ICS)

Arotide (25 mcg+125 mcg)/puff acts through two complementary mechanisms delivered directly to the airway:

• Salmeterol selectively activates beta-2 adrenergic receptors on airway smooth muscle, increasing cyclic AMP and producing sustained relaxation (bronchodilation) lasting about 12 hours.
• Fluticasone propionate binds glucocorticoid receptors within airway cells, switching off pro-inflammatory gene expression and switching on anti-inflammatory pathways, reducing airway inflammation, mucosal edema, and hyperresponsiveness.

The combination provides both symptomatic bronchodilation and disease-modifying anti-inflammatory control, addressing the two central mechanisms of chronic airway obstruction in asthma and COPD.

C (legacy FDA pregnancy category assigned prior to the 2015 Pregnancy and Lactation Labeling Rule; data in pregnant women are insufficient)

The approved pediatric use of Arotide (25 mcg+125 mcg)/puff depends on the specific strength and inhaler device:

• Children 4 years and older: The lowest-strength formulation may be used for asthma maintenance therapy twice daily, strictly as prescribed by a physician, when an inhaled corticosteroid alone has not provided adequate control or when combination therapy is otherwise judged appropriate.
• Children under 4 years: Safety and efficacy have not been established; use is not recommended in this age group.
• COPD in children: Not applicable — COPD does not occur in the pediatric population, and this medicine is not indicated for COPD in children.

Growth (height) should be monitored periodically in children receiving long-term treatment, as inhaled corticosteroids may cause a small reduction in growth velocity.